Articles from Accendra Health, Inc.

Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company’s ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes.

Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations.

Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company’s Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer succession. Through that process, the Board has previously identified potential candidates with the capabilities to succeed Mr. Pesicka. With Mr. Pesicka’s decision and announcement, the Board will leverage that preparation to comprehensively evaluate and select the Company’s next President and CEO. Mr. Pesicka may serve in an advisory capacity beyond his planned retirement date to help ensure a smooth and successful transition.

Accendra Health today announced key leadership appointments in Information Technology and Procurement, reinforcing our commitment to building a stronger operational foundation and positioning the company for long-term growth. These appointments reflect a deliberate shift to better align strategy and execution as we continue our evolution as a pure play home-based care organization dedicated to advancing healthcare in the home and beyond.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on the New York Stock Exchange.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the expiration and final results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”).

Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced the early results of the previously announced offers to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 Notes for newly issued 9.000% Senior Secured First Lien Notes due 2032 (the “First Lien Notes”) and newly issued 9.750% Senior Secured Second Lien Notes due 2033 (the “Second Lien Notes” and, together with the First Lien Notes, the “New Notes”). Eligible Holders of 2029 Notes that do not participate in the New Money Notes Issuance and Eligible Holders of 2030 Notes will be able to exchange such notes for Second Lien Notes.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it has commenced an offer to exchange (the “Exchange Offers”) any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”). Eligible Holders of 2029 Notes that participate in the New Money Notes Issuance (as defined below) will be able to exchange such 2029 Notes for newly issued 9.000% Senior Secured First Lien Notes due 2032 (the “First Lien Notes”) and newly issued 9.750% Senior Secured Second Lien Notes due 2033 (the “Second Lien Notes” and, together with the First Lien Notes, the “New Notes”). Eligible Holders of 2029 Notes that do not participate in the New Money Notes Issuance and Eligible Holders of 2030 Notes will be able to exchange such notes for Second Lien Notes.

Accendra Health, Inc. (NYSE: ACH) today reported financial results for the first quarter ended March 31, 2026, and announced a more than $1.5 billion comprehensive balance sheet optimization transaction with commitments from existing creditors that will strengthen the balance sheet, significantly extend maturities and reduce total leverage. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the first quarter of 2026 on Monday, May 11, 2026, before trading begins on the New York Stock Exchange.

Accendra Health, Inc. (NYSE: ACH) today reported financial results for the fourth quarter ended December 31, 2025. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which primarily represent what was previously the Patient Direct segment and certain functional operations.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the fourth quarter of 2025 on Thursday, February 19, 2026, after trading ends on the New York Stock Exchange.

Accendra Health, Inc. (NYSE: ACH) (the “Company”) announced that the Company’s common stock will begin trading on the New York Stock Exchange under its new ticker symbol, “ACH”, effective today. The Company also announced the launch of its new website, www.accendrahealth.com. On December 31, 2025, the Company announced the completion of the sale of its former Products & Healthcare Services business along with the Owens & Minor brand.